Status:

COMPLETED

Growth Hormone Use in Adults With Prader-Willi Syndrome

Lead Sponsor:

Children's Mercy Hospital Kansas City

Conditions:

Prader-Willi Syndrome

Eligibility:

All Genders

16-60 years

Phase:

PHASE3

Brief Summary

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss...

Detailed Description

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss...

Eligibility Criteria

Inclusion

  • 16 to 60 years old
  • Male or female with diagnosed Prader-Willi syndrome confirmed by genetic testing (e.g., mPCR)
  • Low IGF-1 level (e.g.,≤25%) at baseline
  • Ability to provide informed consent or availability of a suitable legally authorized representative

Exclusion

  • Pregnancy
  • Previous treatment with growth hormone
  • Uncontrolled endocrine disease, (i.e. diabetes or thyroid)
  • History of severe scoliosis
  • Heart disease
  • Uncontrolled high blood pressure or history of stroke
  • Morbid obesity (using PWS growth charts)
  • Severe sleep apnea or known breathing difficulties/obstruction (as per history or diagnostic testing results

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2012

Estimated Enrollment :

11 Patients enrolled

Trial Details

Trial ID

NCT00444964

Start Date

April 1 2005

End Date

January 1 2012

Last Update

January 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Children's Mercy Hospital

Kansas City, Missouri, United States, 64108